evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,181 questions · 1,197 findings · 144 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 196 · 16.4%GRADE not reported 213 · 17.8%Very low 274 · 22.9%Low 296 · 24.7%Moderate 171 · 14.3%High 47 · 3.9%

Gabapentin vs placebo

Treatment withdrawalNumber of participants withdrawn for any reason · people with drug‐resistant focal epilepsy

Gabapentin showed no clear difference in treatment withdrawalNumber of participants withdrawn for any reason compared with placebo (moderate certainty).

1 finding from 1 review

Moxifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen

Treatment failure · adults with drug‐sensitive pulmonary tuberculosis

Moxifloxacin‐containing 4‐month ATT regimens showed no clear difference in treatment failure compared with standard 6‐month ATT regimen (moderate certainty).

1 finding from 1 review

Moxifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen

Acquired drug resistance · adults with drug‐sensitive pulmonary tuberculosis

Moxifloxacin‐containing 4‐month ATT regimens showed no clear difference in acquired drug resistance compared with standard 6‐month ATT regimen (low certainty).

1 finding from 1 review

Gatifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen

Treatment failure · adults with drug‐sensitive pulmonary tuberculosis

Gatifloxacin‐containing 4‐month ATT regimens showed no clear difference in treatment failure compared with standard 6‐month ATT regimens (moderate certainty).

1 finding from 1 review

Gatifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen

Acquired drug resistance · adults with drug‐sensitive pulmonary tuberculosis

It is very uncertain whether gatifloxacin‐containing 4‐month ATT regimens changes acquired drug resistance compared with standard 6‐month ATT regimens (very low certainty).

1 finding from 1 review

CLOZAPINE + AMISULPIRIDE vs CLOZAPINE + QUETIAPINE (Genc 2007)

Leaving the study early · people with treatment‐resistant schizophrenia

It is very uncertain whether CLOZAPINE + AMISULPIRIDE changes leaving the study early: acceptability of treatment ‐ as measured by… compared with CLOZAPINE + QUETIAPINE (Genc 2007) (very low certainty).

1 finding from 1 review

CLOZAPINE + RISPERIDONE vs CLOZAPINE + ZIPRASIDONE (Kuwilsky 2010)

Acceptability of treatment ‐ leaving the study early · people with treatment‐resistant schizophrenia

It is very uncertain whether CLOZAPINE + RISPERIDONE changes leaving the study early: acceptability of treatment ‐ as measured by… compared with CLOZAPINE + ZIPRASIDONE (Kuwilsky 2010) (very low certainty).

1 finding from 1 review

CLOZAPINE + ZIPRASIDONE vs CLOZAPINE + QUETIAPINE (Wen 2015)

Leaving the study early · people with treatment‐resistant schizophrenia

It is very uncertain whether CLOZAPINE + ZIPRASIDONE changes leaving the study early: acceptability of treatment ‐ as measured by… compared with CLOZAPINE + QUETIAPINE (Wen 2015) (very low certainty).

1 finding from 1 review

CLOZAPINE + ARIPIPRAZOLE vs CLOZAPINE + HALOPERIDOL (Cipriani 2013)

Acceptability of treatment ‐ leaving the study early · people with treatment‐resistant schizophrenia

It is very uncertain whether CLOZAPINE + ARIPIPRAZOLE changes leaving the study early: acceptability of treatment ‐ as measured by… compared with CLOZAPINE + HALOPERIDOL (Cipriani 2013) (very low certainty).

1 finding from 1 review

Sildenafil vs placebo

Sexual function: Objective assessment (Global efficacy questionnaire, improved erections) · patients with sexual dysfunction due to antipsychotic drug therapy

ADJUNCTIVE TREATMENT ‐ SPECIFIC: SILDENAFIL may leads to higher sexual function: Objective assessment (Global efficacy… compared with PLACEBO (low certainty).

1 finding from 1 review